Avacta Group (AVCT) News Today GBX 78 -3.00 (-3.70%) As of 12:50 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesBuy This Stock AVCT Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 Time Period Unaudited Preliminary Results for the Year Ended December 31, 2025May 19 at 2:14 AM | globenewswire.comAvacta Group (LON:AVCT) Share Price Crosses Above 200-Day Moving Average - Here's What HappenedMay 16, 2026 | americanbankingnews.comAvacta Group (LON:AVCT) Reaches New 1-Year High - Time to Buy?May 8, 2026 | marketbeat.comAvacta Group (LON:AVCT) Trading Up 15.5% - Here's WhyMay 7, 2026 | marketbeat.comAvacta (AVCT) highlights promising pre|CISION platform results at 2026 Science DayMay 6, 2026 | uk.finance.yahoo.comAvacta presents new comparisons of pre|CISION® payload release vs approved ADCs and AVA6207 dual payload delivery at Science Day 2026May 6, 2026 | globenewswire.comAvacta announces first patient treated in Phase 1 FOCUS-01 trial of FAP-Exd (AVA6103) - a sustained-release pre|CISION® exatecan peptide drug conjugateApril 1, 2026 | finance.yahoo.comAvacta's pre|CISION Mechanism for Payload Delivery Shows Key Advantages Compared to an Antibody Drug Conjugate in Innovative AI-Driven AnalysisFebruary 25, 2026 | markets.businessinsider.comWith 75% institutional ownership, Avacta Group Plc (LON:AVCT) is a favorite amongst the big gunsFebruary 15, 2026 | finance.yahoo.comAvacta Group PLC: Avacta appoints Francis Wilson as Chief Scientific OfficerFebruary 9, 2026 | finanznachrichten.deAvacta Announces U.S. Food and Drug Administration Clearance of the Investigational New Drug (IND) Application for the Second pre|CISION® Medicine, FAP-Exatecan (AVA6103)January 21, 2026 | markets.businessinsider.comAVACTA GROUP PLC: Avacta Announces Year-end Trading UpdateJanuary 20, 2026 | finanznachrichten.deAvacta Announces Year-end Trading UpdateJanuary 20, 2026 | markets.businessinsider.comAvacta reports tumor shrinkage in salivary gland cancer patientsDecember 17, 2025 | za.investing.comThe Avacta share price is up 115.9% in 6 months! Should I buy now?November 10, 2025 | msn.comAvacta presents first preclinical data from dual payload pre|CISION® medicines at the 2025 AACR-NCI-EORTC International Conference on Molecular TargetsOctober 27, 2025 | finance.yahoo.comAVCT - Avacta Group PLC Sustainability - MorningstarJuly 2, 2025 | morningstar.comMAvacta Group Regulatory NewsJune 10, 2025 | lse.co.ukAvacta Therapeutics Announces Appointments of Industry Veterans to Board of DirectorsMay 28, 2025 | finance.yahoo.comAvacta Group PLCApril 30, 2025 | barrons.comAvacta Therapeutics Presents Data from Lead pre|CISION® Candidate FAP-Dox (AVA6000) at the 2025 AACR Annual MeetingApril 30, 2025 | seekingalpha.comAvacta Therapeutics Presents Preclinical and Translational Data from pre|CISION® Platform Candidates at 2025 AACR Annual MeetingApril 28, 2025 | finance.yahoo.comAvacta Provides Business Update for the First Quarter of 2025 Outlining Progress Against Strategic ObjectivesMarch 31, 2025 | uk.finance.yahoo.comAvacta Therapeutics Announces Presentations at 2025 AACR Annual MeetingMarch 26, 2025 | markets.businessinsider.comAvacta Therapeutics reports data from trial of AVA6000 for salivary gland cancerJanuary 17, 2025 | msn.comAvacta Group Opens Phase 1b Trial for Targeted Cancer TherapyDecember 12, 2024 | markets.businessinsider.comInvestors in Avacta Group (LON:AVCT) have seen splendid returns of 163% over the past five yearsNovember 13, 2024 | finance.yahoo.comAvacta Group Share Chat (AVCT)October 3, 2024 | lse.co.ukAvacta Group First Half 2024 Earnings: UK£0.038 loss per share (vs UK£0.043 loss in 1H 2023)October 3, 2024 | uk.finance.yahoo.comAvacta Group Plc (LON:AVCT) Insider Tony Peter Gardiner Sells 500,000 SharesSeptember 4, 2024 | insidertrades.comAvacta Group Plc (AVCTF)July 27, 2024 | uk.finance.yahoo.comAvacta Group Plc reports FY resultsMay 1, 2024 | msn.comAvacta Group (LON:AVCT) investors are sitting on a loss of 82% if they invested three years agoMay 1, 2024 | finance.yahoo.comUpdated Results from Single-Agent Phase 1 Clinical Trial of Peptide Drug Conjugate, AVA6000 to be Presented in a Poster at the American Association of Cancer Research (AACR) Annual Meeting on April 9, 2024March 6, 2024 | finance.yahoo.comAvacta Group: Appointment of Chief Business OfficerDecember 19, 2023 | finanznachrichten.deAppointment of Chief Business OfficerDecember 19, 2023 | finance.yahoo.comALS-6000-101 Phase 1a Three-Weekly Dose Escalation Safety Study DataDecember 13, 2023 | finance.yahoo.comAnixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory BoardOctober 23, 2023 | finance.yahoo.comIf I’d invested £1,000 in Avacta shares 5 years ago, here’s how much I’d have nowSeptember 11, 2023 | msn.comAvacta Group Share ChatAugust 11, 2023 | lse.co.ukAvacta Completes Fifth Dose Escalation in AVA6000 Phase 1 Clinical StudyJune 21, 2023 | marketwatch.comAvacta Group plc: Avacta Announces Successful Completion of Fifth Dose Escalation in AVA6000 Phase 1 Clinical StudyJune 21, 2023 | finanznachrichten.deAvacta Announces Successful Completion of Fifth Dose Escalation in AVA6000 Phase 1 Clinical StudyJune 21, 2023 | finance.yahoo.comAvacta Group Says No Fundraising Imminent; Shares RiseJune 19, 2023 | marketwatch.comAVCT.L - Avacta Group PlcJune 6, 2023 | uk.finance.yahoo.comFirst Patient Dosed in the US in Avacta’s AVA6000 Phase 1 Clinical StudyApril 27, 2023 | finance.yahoo.comAvacta Group plc: Avacta Announces First Patient Dosed in Fifth Cohort of AVA6000 Phase Ia Dose Escalation StudyApril 5, 2023 | finanznachrichten.deAvacta Appoints Karen Harrison as Chief Operating Officer for Therapeutics DivisionMarch 28, 2023 | finance.yahoo.comIs the Avacta share price dip a buying opportunity?March 16, 2023 | msn.comBlock Listing Application to AIMJanuary 17, 2023 | lse.co.uk Get Avacta Group News Delivered to You Automatically Sign up to receive the latest news and ratings for AVCT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AVCT Media Mentions By Week AVCT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AVCT News Sentiment▼-0.450.40▲Average Medical News Sentiment AVCT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AVCT Articles This Week▼30▲AVCT Articles Average Week Get the Latest News and Ratings for AVCT and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Avacta Group and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Oxford Nanopore Technologies News Oxford Biomedica News PureTech Health News Scancell News BTG News Faron Pharmaceuticals Oy News Bioventix News 4basebio News hVIVO News Hemogenyx Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (LON:AVCT) was last updated on 5/21/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avacta Group Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Avacta Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
